Opening of the continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.
As part of GSK and Singapore’s Economic Development Board (GSK-EDB) 10-year Singapore Manufacturing Roadmap, GSK opened new state-of-the-art manufacturing facilities in Singapore following a S$130 million investment.
The launch was officiated by Trade and Industry Minister Chan Chun Sing and Mr Regis Simard, President of Pharma Supply Chain. The new facilities are in GSK’s Jurong site and include two continuous manufacturing facilities, and an expansion of one of the site’s production buildings. The development will enable the site, to accelerate the supply of new breakthrough medicines to patients globally.
As part of GSK Jurong’s R&D Pilot Plan, the new continuous manufacturing facilities will strengthen the site’s capability for drug manufacture by allowing faster production of Active Pharmaceutical Ingredients (APIs) for clinical trials. The first New Chemical Entity (NCE) to be developed at the new facility will be Daprodustat, a new oral treatment for anaemia associated with chronic kidney disease. The new manufacturing process is expected to reduce production time of Daprodustat, enabling faster turnaround time.
The expansion of the production building which makes APIs for HIV medicines will enhance GSK’s capability to produce Dolutegravir, a key GSK asset for HIV treatment. The new facilities also engages the development of digital technologies in the manufacturing process to drive productivity improvement.
The investment demonstrates GSK’s commitment to Singapore as a key manufacturing and supply site for GSK’s global pharmaceutical business and a testbed for advanced manufacturing technology. [APBN]